key: cord-1051378-ev3us9n8
authors: Zhou, Daming; Dejnirattisai, Wanwisa; Supasa, Piyada; Liu, Chang; Mentzer, Alexander J.; Ginn, Helen M.; Zhao, Yuguang; Duyvesteyn, Helen M.E.; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Wang, Beibei; Paesen, Guido C.; Lopez-Camacho, Cesar; Slon-Campos, Jose; Hallis, Bassam; Coombes, Naomi; Bewley, Kevin; Charlton, Sue; Walter, Thomas S.; Skelly, Donal; Lumley, Sheila F.; Dold, Christina; Levin, Robert; Dong, Tao; Pollard, Andrew J.; Knight, Julian C.; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah; James, William; Carroll, Miles W.; Klenerman, Paul; Barnes, Eleanor; Dunachie, Susanna J.; Fry, Elizabeth E.; Mongkolspaya, Juthathip; Ren, Jingshan; Stuart, David I.; Screaton, Gavin R.
title: Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
date: 2021-02-23
journal: Cell
DOI: 10.1016/j.cell.2021.02.037
sha: 2eb7aad1e6f9722ec65c001874768638d9b23d3f
doc_id: 1051378
cord_uid: ev3us9n8

The race to produce vaccines against SARS-CoV-2 began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK–B.1.1.7, South Africa–B.1.351 and Brazil–P.1. These variants have multiple changes in the immunodominant spike protein which facilitates viral cell entry via the Angiotensin converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K although K417N and N501Y act together against some important antibody classes. In a number of cases it would appear that convalescent and some vaccine serum offers limited protection against this variant.

The Pfizer-BioNTech vaccine serum induced 3.6-fold higher neutralization titres against the 202 Victoria strain than the Oxford-AstraZeneca vaccine (p=<0.0001). Although the overall 203 reduction of titres was quite similar, 7.6-fold vs 9-fold respectively, because the AstraZeneca 204 titres started from a lower base more of the samples failed to reach 50% FRNT titres against 205 B.1.351 (9/25) than for the Pfizer vaccine (2/25), although one of these (Pfizer 2) also 206 showed low neutralizing titres to the Victoria virus. The triple mutation K417N, E484R and N501Y is characteristic of the B.1.351 RBD. These 250 residues are situated within the ACE2 footprint ( Figure 1E ) and in vitro evolution to 251 optimise the affinity for ACE2 has suggested that they confer higher affinity for the receptor 252 and only makes hydrophobic contacts to K417 from Y33, Y52 and D104 of the heavy chain. 318

Changing the K to N at 417 in this complex structure and selecting one of the favourable side 319 chain rotamers shows that N417 could make hydrogen bonds to both Y33 and Y52, 320 compensating for the loss of contact to D104 (Figure 5F, 5G) . In 222, Y33 and Y52 are 321 conserved and D104 is replaced by an asparagine. We speculate that the interaction of 222 322 with K417 might be similar to CB6, explaining its resistance to the B.1.351 variant.

Fab 88 binds RBD at the back of the left shoulder, residues G104 and K108 of the HC CDR3 326 contact E484 meanwhile the LC CDR2 makes extensive hydrophobic interactions and a main 327 chain hydrogen bond from Y51 and a salt bridge from D53 to K417 (Figure 5A) . The change 328 of charge at E484 from negative to positive and shortening of the residue 417 side chain from 329 K to N would be expected to abolish all these interactions, explaining the several hundred-330 fold loss in KD. 384 is one of the most potent neutralizing mAbs we have found against the 331 Victoria virus. This mAb approaches the binding site from the front of the left shoulder, 332 burying 82% of the solvent accessible area of E484 by hydrogen bonding with Y50, T57 and 333 Y59 as well as making a salt bridge with R52 of the LC CDR2 (Figure 5D ), explaining the 334 catastrophic impact of the E484K mutation on binding (Table S3) . almost all monoclonal antibodies described to date, is a cause for concern. Whether such 458 viruses with extreme ACE2/RBD affinity are viable is clearly unknown and extreme caution 459 should be exercised as to whether this scenario should ever be tested using live viruses. 460

In summary, the recent emergence of multiple variant strains of SARS-CoV-2 has disrupted 461 confidence around whether the current generation of vaccines will provide long term 462 protection against infection. The possibility of escape from natural and vaccine induced 463 immunity has prompted a rush to understand the consequences of these changes and spurred 464 a push to develop new vaccine constructs tailored to the variants, particularly incorporating 465 the E484K mutation. How previously infected or vaccinated individuals respond to these new 466 variant vaccines will be the subject of intense study over the coming months, as there is a 467 general reckoning that the current problem is not over. However, even if antibody responses 468 to the new variants are not able to prevent infection, they may moderate severity. In addition, 469 T-cell responses to spike may not be disrupted by the mutational changes and be able to limit 470 spread to the lower respiratory tract and prevent severe disease. 471

Intensive surveillance systems need to be implemented to monitor for the emergence of new 473 variants and in particular to be targeted at searching for breakthrough infections in vaccinees. 474

Work on second and even third generation vaccines to target variant viruses and more 475 broadly to develop immunogens to targets less reliance on the ACE2/RBD interaction surface 476 are deserving of further study. 477 478

The vaccine and convalescent samples used in the neutralization studies in this report were 480 taken early and titres may rise further, conversely, it is also likely that titres will wane with 481 time and that protection from B. Table S1 . Table S2 . See also Figure S1 . 591 Table  597 S3. 598 Sera from Pfizer vaccinees 688

Full details of the randomized controlled trial of ChAdOx1 nCoV-19 (AZD1222), were 705 previously published

Written informed consent was obtained from all participants, and the trial is 708 being done in accordance with the principles of the Declaration of Helsinki and Good

The studies were sponsored by the University of Oxford (Oxford, UK) and 710 approval obtained from a national ethics committee

Committee, reference 20/SC/0145 and 20/SC/0179) and a regulatory agency in the United

Kingdom (the Medicines and Healthcare Products Regulatory Agency)

5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit virus 743 diffusion. A focus forming assay was then performed by staining Vero cells with human anti-744 NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG

Finally, the foci (infected cells) approximately 100 per well in the absence of 746 antibodies, were visualized by adding TrueBlue Peroxidase Substrate. Virus-infected cell foci 747 were counted on the classic AID EliSpot reader using AID ELISpot software. The percentage 748 of focus reduction was calculated and IC 50 was determined using the

Cloning of native RBD, ACE2 and RBD K417N

The constructs of native RBD and ACE2 are the same as in

To clone RBD K417N, E484K, N501Y, a construct of RBD with the mutation

2021) was used as the template and four primers of RBD

E484K 757 Forward primer 5'-CACCGTGTAATGGCGTGAAGGGCTTCAATTGCTAC-3' and E484K 758 reverse primer 5'-GTAGCAATTGAAGCCCTTCACGCCATTACACGGTG-3') and two 759 primers of pNEO vector (Forward primer 5'-CAGCTCCTGGGCAACGTGCT-3' and 760 reverse primer 5'-CGTAAAAGGAGCAACATAG-3') were used to do PCR. Amplified 761 DNA fragments were digested with restriction enzymes AgeI and KpnI and then ligated with 762 digested pNEO vector

Briefly, plasmids 767 encoding proteins were transiently expressed in HEK293T (ATCC CRL-11268) cells. The 768 conditioned medium was dialysed

Healthcare) and further polished using a Superdex 75 HiLoad 16/60 gel filtration column

To measure the binding 774 affinities of monoclonal antibodies and ACE2 with native RBD and RBD K417N

N501Y, each RBD was immobilized onto an AR2G biosensor (Fortebio)

2020) were used as analytes or serial dilutions of ACE2 were 777 used as analytes. All experiments were run at 30 °C. Data were recorded using software Data 778

Acquisition 11.1 (Fortebio) and Data Analysis HT 11.1 (Fortebio) with a 1

Neutralization was 784 measured by FRNT. The percentage of focus reduction was calculated and IC 50 was 785 determined using the probit program from the SPSS package.The Wilcoxon matched-pairs 786 signed rank test was used for the analysis and two-tailed P values were calculated and 787 geometric mean values

SARS-CoV-2 escape in vitro from a highly 795 neutralizing COVID-19 convalescent plasma

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 802 mutational escape seen with individual antibodies

Isolation and rapid sharing of the 2019 novel coronavirus

from the first patient diagnosed with COVID-19 in Australia

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-809 Terminal Domain Target a Single Supersite Lead Contact

The Antigenic Anatomy of SARS-CoV-2 Receptor

Efficacy Data Updates from Novavax' Protein-based Vaccine Candidate (2021)

Genomic characterisation of an 823 emergent SARS-CoV-2 lineage in Manaus: preliminary findings -SARS-CoV-2 coronavirus / 824 nCoV-2019 Genomic Epidemiology -Virological, virological.org

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease

SARS-CoV-2 evolution during treatment of 840 chronic infection

The impact of Covid-19, 842 associated behaviours and policies on the UK economy: A computable general equilibrium 843 model

SARS-CoV-2 vaccines in development

Molecular determinants and mechanism for antibody cocktail 847 preventing SARS-CoV-2 escape

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for 850 virus origins and receptor binding

Safety and efficacy of the ChAdOx1 nCoV-19 853 (AZD1222) cOVID-19 vaccine against the B.1.351 variant in South Africa

N-terminal domain antigenic mapping reveals a site of 857 vulnerability for SARS-CoV-2

Tracking the COVID-19 pandemic in Australia 863 using genomics

Structural basis of receptor recognition by SARS-CoV-2

A 867 human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

The COG database: A tool for 877 genome-scale analysis of protein functions and evolution

Sixteen novel lineages of SARS-CoV-2 in

South Africa

vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled Voysey

Single dose administration, and the influence 888 of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1nCoV-19 889 (AZD1222) vaccine

Robust neutralizing antibodies to SARS-CoV-2 892 infection persist for months

COVID-19 antibody therapeutics 894 tracker: a global online database of antibody therapeutics for the prevention and treatment 895 of COVID-19

897 et al. Structural basis of a shared antibody response to SARS-CoV-2

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, 901 yet generates an able infection inhibitor

The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test 737